The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1702-1705

  Bilen, Cenk Yücel ^a   Inci, Kubilay ^a   Erkan, Ihan ^a   Özen, Haluk ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Administration, intravesical; Bladder neoplasms, mycobacterium tuberculosis; Treatment outcome

Indexed keywords

BCG VACCINE; TUBERCULIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; DYSURIA; FEMALE; FEVER; HEMATURIA; HEPATITIS; HUMAN; HYPERSENSITIVITY; HYPOTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RASH; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 0037404236     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000059681.67567.12     Document Type: Article

References (20)

1. Dalbagni, G. and Herr, H. W.: Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am, 27: 137, 2000
2. Mungan, N. A. and Witjes, J. A.: Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol, 82: 213, 1998
3. Torrence, R. J., Kavoussi, L. R., Catalona, W. J. and Ratliff, T. L.: Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J Urol, 139: 941, 1988
4. Lamm, D. L.: Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am, 19: 565, 1992
5. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 116: 180, 1976
6. Patton, S. E., Hall, M. C. and Ozen, H.: Bladder cancer. Curr Opin Oncol, 14: 265, 2002
7. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C. et al: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J Urol, 134: 48, 1985
8. Sokal, J. E., Aungst, C. W. and Han, T.: Effect of BCG on delayed hypersensitivity responses of patients with neoplastic disease. Int J Cancer, 12: 242, 1973
9. Nathanson, L.: Use of BCG in the treatment of human neoplasms: a review. Semin Oncol, 1: 337, 1974
10. Thanhauser, A., Bohle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M. et al: The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother, 40: 103, 1995
11. Starke, J. R.: The tuberculin skin test. Pediatr Ann, 22: 612, 1993
12. Snider, D. E., Jr.: Bacillus Calmette-Guerin vaccinations and tuberculin skin tests. JAMA, 253: 3438, 1985
13. Stanford, J. L.: Immunologically important constituents of mycobacteria: antigens. In: The Biology of the Mycobacteria. Edited by C. Ratledge and J. L. Stanford. New York: Academic Press, vol. 2, chapt. 2, pp. 85-128, 1983
14. Lamm, D. L., van der Meijden, A. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W. et al: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 147: 596, 1992
15. Lamm, D. L., Steg, A., Boccon-Gibod, L., Morales, A., Hanna, M. G., Jr., Pagano, F. et al: Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res, 310: 335, 1989
16. Lüftenegger, W., Ackermann, D. K., Futterlieb, A., Kraft, R., Minder, C. E., Nadelhaft, P. et al: Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol, 155: 483, 1996
17. Okamura, T., Tozawa, K., Yamada, Y., Sakagami, H., Ueda, K. and Kohri, K.: Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. J Urol, 156: 967, 1996
18. Badalament, R. A., Herr, H. W., Wong, G. Y., Gnecco, C., Pinsky, C. M., Whitmore, W. F., Jr. et al: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol, 5: 441, 1987
19. Rook, G. A. W., Bahr, G. M. and Stanford, J. L.: The effect of two distinct forms of cell mediated response to mycobacteria on the protective efficacy of BCG. Tubercle, 62: 63, 1975
20. Zlotta, A. R., Drowart, A., Huygen, K., De Bruyn, J., Shekarsarai, H., Decock, M. et al: Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol, 109: 157, 1997